Inactive Instrument

Highlights Mira IV Acquisition Corp Toronto S.E.

Equities

MRYp

CA60456Q1054

End-of-day quote Toronto S.E. Other stock markets
-	-

15/05	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
14/05	Sector Update: Health Care Stocks Steady Premarket Tuesday	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Tuesday	14/05	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	14/05	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	14/05	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	14/05	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	10/05	MT
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	10/05	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	10/05	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	10/05	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	07/05	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	07/05	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	07/05	MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	08/03	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	08/03	MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	08/03	MT
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	27/02	MT
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	27/02	CI
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure	27/02	MT
Profound Medical Brief: Adds Top priorities for 2024 will be to further increase Its TULSA-PRO installed base, support increased system utilization, complete its ongoing Level 1 CAPTAIN trial	04/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mira IV Acquisition Corp Toronto S.E.

Equities

MRYp

CA60456Q1054

Highlights

Filters